10.27.2022
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a...
In the News
In The News
Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below. If you’re a media representative, please feel free to contact our media relations office at mediarelations@ebsi.com.
Should you be interested in learning more about Emergent BioSolutions Inc.(NYSE: EBS), please visit our corporate Newsroom.
09.01.2022
EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics
For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic...
03.21.2022
Four Key Considerations to Help Prepare for the Next Public Health Threat
As a CDMO, Emergent has been working for more than two decades to develop, manufacture, and deliver protections against public...
03.14.2022
Emergent Announces Additions to Leadership Team
Emergent is pleased to announce the addition of two senior leaders to its CDMO and Quality & Compliance organizations.
03.11.2022
The Path to Reemergence
Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma...
07.23.2021
Arrival of the Groninger INTEGRA
With the expansion of our viral drug product manufacturing facility in Rockville, Maryland well underway, we have begun...